The first 100 days in office sets the tone for any new president. Similarly, Motley Fool CAPS keeps an eye on how well investors do in their first 100 days. Some of our best -- we call them All-Stars -- have achieved scores of 100 on stock selections in their first 100 days on CAPS. We can look at some of our best players who excelled early on and see which stocks they now think will do best.

One of our highest-rated CAPS members is pshea12, who sports an impressive 99.90 member rating. Since becoming a member in April 2008, pshea12 has made almost 1,000 stock picks, of which 174 are active now. Achieving 76% accuracy, pshea12 has already attracted 27 "groupies," CAPS players who've listed this investor as one of their favorites.

Here are a few of this top member's most recent stock selections and how they were rated.


CAPS Rating (5 max)



Current Score






Direxion Emerging Markets Bull 3X Shares 





Humana (NYSE:HUM)





Isis Pharmaceuticals (NASDAQ:ISIS)





Myriad Genetics





PepsiCo (NYSE:PEP)





RTI International Metals





Teva Pharmaceutical





Watson Pharmaceuticals





Source: Motley Fool CAPS; *price when call was made. Current score is how many points by which a member is beating (lagging) the S&P 500 index from the time of the call.

Let's take a look at what other CAPS members are saying about one of these stocks and whether they agree with this top player's assessment.

Degree of risk
No, antisense is not something out of the new Star Trek movie, but rather a technology that interrupts the abnormal production of proteins often associated with diseases. Isis Pharmaceuticals is one of the leading developers of antisense technology, and its Vitravene has been on the market since 1998. It has another potential blockbuster in the pipeline:  mipomersen to treat high cholesterol (where do I sign up?).

Partnerships with major companies like Merck (NYSE:MRK), Pfizer (NYSE:PFE), and GlaxoSmithKline (NYSE:GSK) mean Isis Pharmaceuticals gets a steady stream of lucrative royalty payments. CAPS member mikethejoker believes the technology and the licensing agreements are a ticket to big growth -- but the road may be bumpy.

I like their very strong position in RNA-based therapeutics. Granted, the whole antisense approach to drug development may be a flop, but these guys have the cash on hand and licensing agreements in place to stick around long enough to find out -- without dilution. Risky but more than enough reward potential to make it worthwhile. But be prepared for a rollercoaster ride!

A 1-in-100 opportunity
See how some of the smartest members in the CAPS investor intelligence community have made their mark? It pays to start your own research on these stocks on Motley Fool CAPS. Read a company's financial reports, scrutinize key data and charts, and examine the comments your fellow investors have made -- all from a stock's CAPS page.

As hockey great Wayne Gretzky once noted, "You miss 100% of the shots you never take." At Motley Fool CAPS, every investor's opinion counts. It's free to sign up, so why not use this opportunity to take your best shot?

Pfizer is a Motley Fool Inside Value recommendation. PepsiCo is an Income Investor pick. GlaxoSmithKline used to be an Income Investor recommendation. Try any of our Foolish newsletters today, free for 30 days.

Fool contributor Rich Duprey owns shares of Merck but does not have a financial position in any of the other stocks mentioned in this article. You can see his holdings. The Motley Fool has a disclosure policy.